German Center for Infection Research

German Center for Infection Research
Name	German Center for Infection Research
Native name	Deutsches Zentrum für Infektionsforschung
Acronym	DZIF
Formation	2011
Type	Research consortium
Headquarters	Braunschweig and Berlin
Leader title	Spokesperson
Leader name	Thomas Schulz
Parent organization	Helmholtz Association; Leibniz Association; Max Planck Society

German Center for Infection Research

The German Center for Infection Research is a national translational research consortium that coordinates biomedical research institutes, university medical facultys, and clinical university hospitals to combat infectious diseases. It links basic science from Max Planck Society and Helmholtz Association institutes with clinical application at Charité – Universitätsmedizin Berlin, University of Heidelberg and other major medical centers, focusing on pathogens such as Mycobacterium tuberculosis, HIV/AIDS, Influenza virus, SARS-CoV-2, and Ebola virus disease. The center aims to accelerate vaccine development, diagnostics, and antimicrobial strategies through collaborative networks, technology platforms, and coordinated funding.

History

The center was established in 2011 following strategic discussions among the Federal Ministry of Education and Research (Germany), state ministries in the Federal Republic of Germany, and leaders of research organizations including the Helmholtz Association, the Leibniz Association, the Max Planck Society, and the German Research Foundation. Its founding responded to outbreaks such as the 2009 flu pandemic and lessons from the Ebola virus epidemic in West Africa (2013–2016), and to translational models exemplified by the Wellcome Trust and the National Institutes of Health's translational branches. Initial governance drew on expertise from directors at institutions such as Bernhard Nocht Institute for Tropical Medicine and Robert Koch Institute, and it expanded amid the COVID-19 pandemic to coordinate clinical trials and serosurveillance.

Organization and governance

The consortium is organized into site-based hubs that include university medical centers, non-university research institutes, and partner organizations; prominent nodes include Charité – Universitätsmedizin Berlin, Universitätsklinikum Hamburg-Eppendorf, University Hospital Tübingen, and University Hospital Cologne. Governance features a Board of Directors, a Strategic Advisory Board with representatives from the European Centre for Disease Prevention and Control, the World Health Organization, and industrial partners such as Bayer AG and BioNTech SE. Operational oversight involves clinical trial offices, biobanking governance aligned with standards from the European Research Infrastructure Consortium and ethical review by institutional ethics committees at participating universities. The center coordinates with national public-health authorities including the Robert Koch Institute and collaborates with regional ministries in the Free State of Bavaria and North Rhine-Westphalia.

Research programs and priorities

Research priorities span translational pipelines: pathogen discovery and surveillance, host–pathogen interaction, vaccine and therapeutic development, diagnostics, and antimicrobial resistance. Programs interlink basic laboratories studying innate immunity pathways at Max Planck Institute for Infection Biology with clinical trial units conducting phase I–III studies modeled on protocols from European Medicines Agency submissions. The center runs research projects addressing antimicrobial resistance involving partners such as Paul-Ehrlich-Institut, and engages in One Health-oriented studies with veterinary institutes like the Friedrich-Loeffler-Institut. Priority pathogens have included enteric infections such as Vibrio cholerae, vector-borne agents like Plasmodium falciparum, and respiratory viruses exemplified by Middle East respiratory syndrome coronavirus research collaborations.

Collaborating institutions and network

The consortium comprises partner institutions across Germany: universities such as University of Bonn, University of Freiburg, Ludwig Maximilian University of Munich, and research centers including the Bernhard Nocht Institute for Tropical Medicine, Friedrich Miescher Institute, and DZIF-affiliated translational units. International collaborations extend to networks like the European Clinical Research Infrastructure Network, the Coalition for Epidemic Preparedness Innovations (CEPI), and academic partners at University of Oxford, Imperial College London, Harvard T.H. Chan School of Public Health, and the Institut Pasteur. Industry partnerships include vaccine developers and diagnostics firms such as BioNTech SE, Curetis, and global pharmaceutical companies. The network maintains biobanks, cohorts, and data-sharing agreements with repositories used by the European Molecular Biology Laboratory and the Global Health Network.

Funding and infrastructure

Funding is a mixed model: core federal grants from the Federal Ministry of Education and Research (Germany) and matching state funds, competitive project grants from the German Research Foundation, and collaborative funding from European programs such as Horizon 2020 and Horizon Europe. Infrastructure investments have supported high-containment biosafety level 3 laboratories at partner sites, centralized biobanking, high-throughput sequencing platforms compatible with European Nucleotide Archive submissions, and clinical trial units certified to international good clinical practice standards as used by the European Clinical Trials Directive. The center leverages in-kind contributions from partner institutions and translational funding mechanisms similar to those employed by the Wellcome Sanger Institute and national translational initiatives.

Training, outreach, and public health impact

Training activities include doctoral programs with universities like Heinrich Heine University Düsseldorf, postgraduate clinical trials training in collaboration with European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and courses offered jointly with the Bernhard Nocht Institute for Tropical Medicine and London School of Hygiene & Tropical Medicine. Outreach emphasizes public communication during outbreaks, policy briefs for ministries patterned after WHO recommendations, and capacity building in low-resource settings through partnerships with African Academy of Sciences and Ifakara Health Institute. The center’s translational outputs have influenced national vaccine strategy deliberations at the Standing Committee on Vaccination (STIKO) and contributed diagnostic assays adopted by the Robert Koch Institute for surveillance.

Category:Medical research institutes in Germany Category:Infectious disease organizations